Good Samaritan Society Hospice Medicare Approved Location: 24090 Smiley Road, Suite 200, Nisswa, Minnesota 56468 Phone: (218) 963-9452 |
News Archive
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
"Most Americans are worried about the federal deficit and say the government should cut spending, but few are willing to embrace specific cuts, according to a Pew Research Center survey released Friday," the Huffington Post's "Politics" blog reports.
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from pre-existing moles, but the majority of them come from sources unknown – until now.
Ethiopia has taken crucial steps to fight the HIV/AIDS pandemic, but the east African country urgently needs external assistance if its efforts are to meet with success, a senior United Nations official said today.
› Verified 9 days ago